Health Care·Pharmaceuticals·$6.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.88 | N/A | -66.04% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.88 | N/A | -66.04% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current operational hurdles. They are focused on improving efficiency but did not provide specific strategies.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts to streamline operations.
No specific plans were outlined for future product launches.
Terns Pharmaceutical's earnings report shows a significant miss on EPS, which may raise concerns among investors about the company's financial health. The stock reacted by declining 1.24%, reflecting investor apprehension. Without revenue figures or guidance, uncertainty remains about the company's future performance and strategy.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AIR PRODS & CHEMS IN
May 10, 2021